Related Posts

• 
  Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson’s disease to inform clinical trial designs
• 
  The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
• 
  Molecular Neuroimaging of the Dopamine Transporter (DAT) as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson Disease
• 
  New Frontiers in Parkinson’s Disease: From Genetics to The Clinic
• 
  Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson’s Disease Clinical Trials: A Disease Progression Modeling Analysis